References
- Mauri L, Hsieh W, Massaro JM, Ho KKL, D’Agostino R, Cutlip DE. (2007). Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med, 356, 1020–9.
- Kukreja N, Onuma Y, Daemen J, Serruys PW. (2008). The future of drug-eluting stents. Pharmacol Res, 57, 171–80.
- Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. (2008). A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet, 371, 899–907.
- Kim HI, Takai M, Ishihara K. (2009). The bioabsorbable materials containing phosphorylcholine group-rich surfaces for temporary scaffolding of the vessel wall. Tissue Eng, doi: 10.1089/ten.tea.2008.0307.
- Dzau VJ, Braun-Dullaes RC, Sedding DG. (2002). Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med, 8, 1249–56.
- Rainer W, Blaich B, BelAiba RS, Merl S, Görlach A, Kastrati A. (2007). Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Thromb Haemost, 97, 1003–12.
- Serruys PW, Kutryk MJB, Ong ATL. (2006). Coronary-artery stents. N Engl J Med, 354, 483–95.
- Wang X, Venkatraman SS, Boey FYC, Loo JSC, Tan LP. (2006). Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials, 27, 5588–95.
- Alexis F, Venkatraman SS, Rath SK, Boey F. (2004). In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J Contr Rel, 98, 67–74.
- Ferron GM, Jusko WJ. (1998). Species differences in sirolimus stability in humans, rabbits, and rats. Drug Metab Dispos, 26, 83–4.
- Trepanier DJ, Gallant H, Legatt DF, Yatscoff RW. (1998). Rapamycin: distribution, pharmacokinetics and therapeutic range investigations: an update. Clin Biochem, 31, 1345–51.
- Duncan R. (2003). The dawning era of polymer therapeutics. Nat Rev Drug Discov, 2, 347–60.
- Diab C, Tribet C, Gohon Y, Popot J-L, Winnik FM. (2007). Complexation of integral membrane proteins by phosphorylcholine-based amphipols. Biochim Biophys Acta, 1768, 2737–47.
- Gohon Y, Giusti F, Prata C, Charvolin D, Timmins P, Ebel C, Tribet C, Popot J -L. (2006). Well-defined nanoparticles formed by hydrophobic assembly of a short and polydisperse random terpolymer, amphipol A8-35. Langmuir, 22, 1281–90.
- Ishihara K, Iwasaki Y, Nakabayashi N. (1999). Polymeric lipid nanosphere consisting of water-soluble poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate). Polym J, 31, 1231–6.
- Konno T, Watanabe J, Ishihara K. (2003). Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phophorylcholine polymers. J Biomed Mater Res,65A, 210–5.
- Wada M, Jinno H, Ueda M, Ikeda T, Kitajima M, Konno T, Watanabe J, Ishihara K. (2007). Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxiel. Anticancer Res, 27, 1431–6.
- Pires NMM, van der Hoeven BL, de Vries MR, Havekes LM, van Vlijmen BJ, Hennink WE, Quax PHA, Jukema JW. (2005). Local perivascular delivery of anti-restenotic agents from a drug- eluting poly(ϵ-caprolactone) stent cuff. Biomaterials, 26, 5386–94.
- Ricciutelli M, Martino PD, Barboni L, Martelli S. (2006). Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC. J Pharm Biomed, 41, 1070–4.
- Diab C, Winnik FM, Tribet C. (2007). Enthalpy of interaction and binding isotherms of non-ionic surfactants onto micellar amphiphilic polymers (amphipols). Langmuir, 23, 3025–35.
- Tada S, Tarbell JM. (2004). Internal elastic lamina affects the distribution of macromolecules in the arterial wall: a computational study. Am J Physiol Heart Circ Physiol, 287, 905–13.
- Balakrishnan B, Dooley J, Kopia G, Edelman ER. (2008). Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Contr Rel. 131, 173–180.